Produces various strains of dried cannabis for medical and recreational use. Manufactures cannabis oil and capsules for medical patients. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
The growth engine is running at low revs right now. Report-card grade: 16/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 42/100.
On our five-subject report card, ACB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
One-line summary: few numbers, an untested story. Keep watching.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.